<DOC>
	<DOCNO>NCT02052323</DOCNO>
	<brief_summary>The purpose study determine parasitological clearance rate microscopy 72-hour period first artesunate dose subject uncomplicated P. falciparum malaria .</brief_summary>
	<brief_title>Harmonized AS/MQ Efficacy Study - Thailand</brief_title>
	<detailed_description>Project Summary Objectives Primary Objective 1 . To determine parasitological clearance rate microscopy 72-hour period first artesunate dose subject uncomplicated P. falciparum malaria Secondary Objectives 2.1 . To describe clinical parasitological outcome subject uncomplicated P. falciparum malaria treat AS-MQ administer sequentially . 2.2 . To measure gametocyte carriage rate subject uncomplicated malaria treatment . 2.3 . To monitor drug level associate artesunate-mefloquine treatment failure . 2.4 . To determine vitro drug sensitivity profile fresh parasite malaria-infected subject prior artesunate-mefloquine treatment time parasite recurrence . 2.5 . To identify specific genetic determinant artemisinin resistance derive parasite population . 2.6 . To correlate clinical outcome vivo study vitro antimalarial drug sensitivity responses molecular genotyping . 2.7 . To compare P. falciparum malaria artemisinin resistance genotype three site three continent , use clinical parasitological outcome , vitro drug sensitivity profile , molecular marker generate use harmonized methodology . 2.8 . To determine contribution host immunity parasitological clinical outcome . 2.9 . To create catalog parasite sample closely correlate clinical datasets longitudinally track resistance trend . Subject Population Subjects age 5-65 year , meet study entry criterion draw local community . Study Site The study base Kwai River Christian Hospital ( KRCH ) Sangklaburi District , Kanchanaburi Province , Thailand , locate 360km northwest Bangkok near Thailand-Myanmar border . Additional site Thailand , include Sai Yok District , Kanchanaburi Province , may add enrolment Sangklaburi insufficient . Number Subjects Up 100 subject enrolled ensure minimum 59 subject complete study activity . This allow 40 % subject drop otherwise unevaluable . Up 200 subject may screen achieve require number evaluable subject . A subject consider evaluable 72 hour commencement artesunate treatment asexual parasite clear peripheral blood base microscopy , whichever longer . Treatment The antimalarial drug regimen evaluate : artesunate ( AS ) 4mg/kg mouth daily 0 , 24 48 hour ; plus mefloquine ( MQ ) 15mg/kg mouth 72 hour , 10mg/kg mouth 84-96 hour ; plus primaquine ( PQ ) 0.5mg/kg single dose mouth 84-96 hour . Study Design Methodology This open-label , single-arm evaluation AS-MQ combination treatment uncomplicated P. falciparum malaria . Subjects remain in-patients completion antimalarial treatment follow weekly 42 day . Study Endpoints Primary Endpoint 1 . Parasite clearance rate define slope linear portion logarithm parasite clearance curve use microscopy determine parasitemia Secondary Endpoints 2.1 . A description clinical parasitological feature uncomplicated malaria set ( composite endpoint ) , include : - Parasite clearance rate first 72 hour artesunate administration define slope linear portion logarithm parasite clearance curve use qPCR determine parasitemia - Parasite reduction ratios 24 48 hour assess microscopy qPCR - Time parasite count fall 50 % , 90 % , 99 % 100 % initial parasite density - Fever clearance time ( i.e . time take temperature fall 38.0˚C ( tympanic method ) 37.5˚C ( axillary method ) remain least 24 hour ) - 42-day PCR-adjusted treatment efficacy use World Health Organization classification outcome . 2.2 . Gametocyte carriage rate assess person week ( 42 day ) 2.3 . Plasma level AS , DHA MQ select time point 2.4 . In vitro IC50 , IC90 , IC99 P. falciparum response panel antimalarial drug , include dihydroartemisinin ( DHA ) mefloquine . 2.5 . Parasite molecular marker drug resistance determine GWAS , SNP analysis genotyping methodology 2.6 . A detailed characterization drug-resistant malaria use integrated endpoint , include clinical , vitro molecular 2.7 . Comparison clinical parasitological outcome vitro molecular feature parasites harmonized site Kenya Peru . 2.8 . Identification host factor correlate slow parasite clearance clinical outcome 2.9 . Creation well-characterised catalog malaria parasites future research</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Thai nonThai , otherwise healthy , male female , age 5 year 65 year inclusive Acute uncomplicated P. falciparum malaria monoinfection , confirm positive blood smear Asexual P. falciparum parasitaemia 1,000 200,000 parasites/µL , confirm thin thick blood film Fever define ≥ 38.0°C tympanic temperature ( equivalent ) history fever within last 24 hour Willingness participate study evidence write informed consent subject parent/guardian ( child ) , assent ( child ) Exclusion criterion : Severe malaria define WHO criterion ( reference WHO 2012 ) Inability eat drink , inability tolerate oral antimalarial medication , recent history seizure ( one previous 24 hour ) , alter level consciousness , inability sit stand Mixed specie asexual stage malaria infection determine microscopy Recent antimalarial treatment , define clear history antimalarial medication take within previous 7 day ; clear history mefloquine within previous 4 week History splenectomy Pregnancy nursing mother Known hypersensitivity artesunate , mefloquine primaquine PI determine best interest subject participate trial</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>P.f Malaria , Artemisinin resistance , ACT treatment failure</keyword>
</DOC>